Search results
Showing 751 to 765 of 2548 results for methods
In development Reference number: GID-TA11554 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Evidence-based recommendations on Kurin Lock for blood culture collection.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
In development Reference number: GID-HST10054 Expected publication date: 20 February 2026
In development Reference number: GID-TA11279 Expected publication date: 21 January 2026
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
In development Reference number: GID-TA11559 Expected publication date: TBC
In development Reference number: GID-TA10977 Expected publication date: TBC
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]
In development Reference number: GID-TA11478 Expected publication date: 11 March 2026
Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation (IPG636)
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.
View recommendations for IPG636Show all sections
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.